Beyond the LVEF: Modernizing Pharmacovigilance and Cardiovascular Risk Management in Early-Phase Clinical Trials
Global Journal of Critical Care and Emergency Medicine · 30.06.2026 · 3 (2)
DOI: 10.33425/3065-5641.1027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Journal of Critical Care and Emergency Medicine, online erschienen am 30.06.2026. Verfasst von Mario Alejandro Castellanos U.
Abstract (Originalsprache)
Background
Traditional pharmacovigilance (PV) has historically relied on reactive functional changes, such as a decrease in Left Ventricular Ejection Fraction (LVEF). However, the emergence of targeted therapies demands a shift toward proactive, molecular-level surveillance [1].
Objective
This article explores modern strategies for cardiac signal detection in early- phase trials, emphasizing the integration of high-sensitivity biomarkers and advanced imaging [2].
Conclusion
Modernizing PV through "Precision MPharmacovigilance (PV), Drug safety surveillance, Adverse drug reactions (ADR), Signal detection, Risk management.onitoring" enhances participant safety and prevents premature attrition of drug candidates [3].
Zitieren
APA
U, M. A. C. (2026). Beyond the LVEF: Modernizing Pharmacovigilance and Cardiovascular Risk Management in Early-Phase Clinical Trials. Global Journal of Critical Care and Emergency Medicine, 3(2). https://doi.org/10.33425/3065-5641.1027
Vancouver
U MAC. Beyond the LVEF: Modernizing Pharmacovigilance and Cardiovascular Risk Management in Early-Phase Clinical Trials. Global Journal of Critical Care and Emergency Medicine. 2026;3(2). doi:10.33425/3065-5641.1027
BibTeX
@article{U2026,
author = {U, Mario Alejandro Castellanos},
title = {Beyond the LVEF: Modernizing Pharmacovigilance and Cardiovascular Risk Management in Early-Phase Clinical Trials},
journal = {Global Journal of Critical Care and Emergency Medicine},
year = {2026},
volume = {3},
number = {2},
doi = {10.33425/3065-5641.1027}
}
EUVIMED